Corium International Inc. (CORI) 7.00 $CORI
Corium incurs higher Q1 fiscal 2015 net loss of USD6.8m
M2 - Wed Feb 11, 5:03AM CST
Biopharmaceutical company Corium International (NasdaqGM:CORI) stated on Tuesday that recorded a net loss of USD6.8m (USD0.37 per share on a fully-diluted basis) for the first fiscal quarter ended 31 December 2014.
CORI: 7.00 (-0.05)
Corium International's (CORI) CEO Peter Staple on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 7:53PM CST
CORI: 7.00 (-0.05)
Corium reports 1Q loss
Automated Insights - Tue Feb 10, 4:36PM CST
MENLO PARK, Calif. (AP) _ Corium International Inc. (CORI) on Tuesday reported a loss of $6.8 million in its fiscal first quarter.
CORI: 7.00 (-0.05)
Corium misses by $0.13, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 3:24PM CST
CORI: 7.00 (-0.05)
Corium Reports First Quarter Fiscal 2015 Financial Results
GlobeNewswire - Tue Feb 10, 3:08PM CST
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results from operations for the first fiscal quarter ended December 31, 2014. Corium's fiscal years end on September 30.
CORI: 7.00 (-0.05)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 2.98 (unch), INSM: 17.40 (+0.69), RNN: 0.75 (+0.01), ZSPH: 46.77 (+3.42), RDHL: 12.69 (+0.04), ASPX: 65.76 (+2.76), ACUR: 0.55 (+0.01), XNPT: 6.69 (-0.21), SPNC: 33.69 (-0.06), CORI: 7.00 (-0.05), SAGE: 41.03 (-0.07), EBIO: 10.13 (+0.05), HAE: 42.94 (-0.59), JAZZ: 169.69 (+6.89), ICPT: 209.12 (+7.12), NVDQ: 15.12 (+0.51)
Corium to Report First Quarter Fiscal 2015 Financial Results on Tuesday, February 10, 2015
GlobeNewswire - Tue Feb 03, 3:18PM CST
Corium International, Inc. (Nasdaq:CORI) today announced that it will report financial results for the First Quarter Fiscal 2015 on Tuesday, February 10, 2015 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results.
CORI: 7.00 (-0.05)
Corium to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Fri Jan 30, 12:55PM CST
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium's President and Chief Executive Officer, will present at the 2015 Leerink Global Healthcare Conference, Wednesday, February 11, 2015 at the Waldorf Astoria New York hotel.
CORI: 7.00 (-0.05)
Robbins Arroyo LLP Is Investigating the Officers and Directors of Corium International, Inc. (CORI) on Behalf of Shareholders
PR Newswire - Wed Jan 21, 1:55PM CST
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Corium International, Inc. (NASDAQGM: CORI) breached their fiduciary duties to shareholders. Corium is a biopharmaceutical company focused on the research, development, manufacture, and commercialization of specialty pharmaceutical products.
CORI: 7.00 (-0.05)
Corium International (CORI) Jumps: Stock Rises 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 16, 8:25AM CST
Corium International (CORI) was a big mover last session, with shares rising nearly 14% on the day.
IPXL: 39.51 (+0.69), CORI: 7.00 (-0.05)
Corium Announces Appointment of Ivan Gergel, M.D. to Board of Directors
GlobeNewswire - Mon Dec 08, 4:12PM CST
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the appointment of Ivan Gergel, M.D. to the Company's Board of Directors.
CORI: 7.00 (-0.05)
Corium concludes revised expanded term loan facility with CRG
M2 - Fri Dec 05, 4:27AM CST
Biopharmaceutical company Corium International (NasdaqGM:CORI) said on Thursday that it has completed its revised term loan facility with CRG and certain of its affiliate funds.
CORI: 7.00 (-0.05)
Corium Announces Closing of Expanded Term Loan Facility With CRG
GlobeNewswire - Thu Dec 04, 3:05PM CST
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that it has closed an expanded term loan facility with CRG and certain of its affiliate funds. The revised Term Loan Agreement provides an additional $10 million to the Company from CRG, which increases the aggregate principal loan amount to $45 million from the $35 million of outstanding principal provided for under the original agreement in July 2012. This revised term loan extends the maturity date of all debt to CRG from June 2017 to June 2019. Corium has drawn down the additional $10 million of principal available from this debt facility, primarily for use in supporting the advancement of its product development programs and proprietary technologies.
CORI: 7.00 (-0.05)
Corium International (CORI) Jumps: Stock Moves 14.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 8:25AM CST
Corium International (CORI) was a big mover last session, with shares rising over 14% on the day.
IPXL: 39.51 (+0.69), CORI: 7.00 (-0.05), AKRX: 47.28 (-0.25), MYL: 55.85 (+1.34)
Corium net loss improves in FY2014
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 6:26AM CST
CORI: 7.00 (-0.05)
Corium beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 3:15PM CST
CORI: 7.00 (-0.05)
Corium Reports Fiscal Year-End 2014 Financial Results and Recent Corporate Developments
GlobeNewswire - Mon Nov 17, 3:05PM CST
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the fiscal year ended September 30, 2014 and reported on recent corporate developments.
CORI: 7.00 (-0.05)
Corium to Report Fiscal Year-end 2014 Financial Results on Monday, November 17, 2014
GlobeNewswire - Tue Nov 11, 3:05PM CST
Corium International, Inc. (Nasdaq:CORI) today announced that it will report financial results for the fiscal year ended September 30, 2014 on Monday, November 17, 2014 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results.
CORI: 7.00 (-0.05)
Corium International (CORI) Jumps: Stock Adds 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 8:52AM CDT
Corium International (CORI) was a big mover last session, with shares rising nearly 9% on the day.
MNK: 115.01 (+2.51), LCI: 57.78 (-0.91), CORI: 7.00 (-0.05), CEMP: 27.68 (+1.25)
Leon Cooperman Picks Ocwen, Altisource Tumble
at The Street - Tue Oct 21, 2:30PM CDT
Corinthian Colleges Inc (NASDAQ:COCO), Gulf Coast Ultra Deep Royalty Trust – Royalty Trust Unit (NASDAQ:GULTU) and Corium International Inc (NASDAQ:CORI) are making notable climbs on the marke...
CORI: 7.00 (-0.05), ASPS: 22.32 (+0.09), OCN: 9.10 (+0.09), COCO: 0.02 (-0.01), GULTU: 0.99 (-0.01)
Corium incurs higher Q1 fiscal 2015 net loss of USD6.8m
M2 - Wed Feb 11, 5:03AM CST
Biopharmaceutical company Corium International (NasdaqGM:CORI) stated on Tuesday that recorded a net loss of USD6.8m (USD0.37 per share on a fully-diluted basis) for the first fiscal quarter ended 31 December 2014.
CORI: 7.00 (-0.05)
Corium International's (CORI) CEO Peter Staple on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 7:53PM CST
CORI: 7.00 (-0.05)
Corium reports 1Q loss
Automated Insights - Tue Feb 10, 4:36PM CST
MENLO PARK, Calif. (AP) _ Corium International Inc. (CORI) on Tuesday reported a loss of $6.8 million in its fiscal first quarter.
CORI: 7.00 (-0.05)
Corium misses by $0.13, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 3:24PM CST
CORI: 7.00 (-0.05)
Corium Reports First Quarter Fiscal 2015 Financial Results
GlobeNewswire - Tue Feb 10, 3:08PM CST
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results from operations for the first fiscal quarter ended December 31, 2014. Corium's fiscal years end on September 30.
CORI: 7.00 (-0.05)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 2.98 (unch), INSM: 17.40 (+0.69), RNN: 0.75 (+0.01), ZSPH: 46.77 (+3.42), RDHL: 12.69 (+0.04), ASPX: 65.76 (+2.76), ACUR: 0.55 (+0.01), XNPT: 6.69 (-0.21), SPNC: 33.69 (-0.06), CORI: 7.00 (-0.05), SAGE: 41.03 (-0.07), EBIO: 10.13 (+0.05), HAE: 42.94 (-0.59), JAZZ: 169.69 (+6.89), ICPT: 209.12 (+7.12), NVDQ: 15.12 (+0.51)
Corium to Report First Quarter Fiscal 2015 Financial Results on Tuesday, February 10, 2015
GlobeNewswire - Tue Feb 03, 3:18PM CST
Corium International, Inc. (Nasdaq:CORI) today announced that it will report financial results for the First Quarter Fiscal 2015 on Tuesday, February 10, 2015 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results.
CORI: 7.00 (-0.05)
Corium to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Fri Jan 30, 12:55PM CST
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium's President and Chief Executive Officer, will present at the 2015 Leerink Global Healthcare Conference, Wednesday, February 11, 2015 at the Waldorf Astoria New York hotel.
CORI: 7.00 (-0.05)
Robbins Arroyo LLP Is Investigating the Officers and Directors of Corium International, Inc. (CORI) on Behalf of Shareholders
PR Newswire - Wed Jan 21, 1:55PM CST
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Corium International, Inc. (NASDAQGM: CORI) breached their fiduciary duties to shareholders. Corium is a biopharmaceutical company focused on the research, development, manufacture, and commercialization of specialty pharmaceutical products.
CORI: 7.00 (-0.05)
Corium International (CORI) Jumps: Stock Rises 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 16, 8:25AM CST
Corium International (CORI) was a big mover last session, with shares rising nearly 14% on the day.
IPXL: 39.51 (+0.69), CORI: 7.00 (-0.05)
Corium Announces Appointment of Ivan Gergel, M.D. to Board of Directors
GlobeNewswire - Mon Dec 08, 4:12PM CST
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the appointment of Ivan Gergel, M.D. to the Company's Board of Directors.
CORI: 7.00 (-0.05)
Corium concludes revised expanded term loan facility with CRG
M2 - Fri Dec 05, 4:27AM CST
Biopharmaceutical company Corium International (NasdaqGM:CORI) said on Thursday that it has completed its revised term loan facility with CRG and certain of its affiliate funds.
CORI: 7.00 (-0.05)
Corium Announces Closing of Expanded Term Loan Facility With CRG
GlobeNewswire - Thu Dec 04, 3:05PM CST
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that it has closed an expanded term loan facility with CRG and certain of its affiliate funds. The revised Term Loan Agreement provides an additional $10 million to the Company from CRG, which increases the aggregate principal loan amount to $45 million from the $35 million of outstanding principal provided for under the original agreement in July 2012. This revised term loan extends the maturity date of all debt to CRG from June 2017 to June 2019. Corium has drawn down the additional $10 million of principal available from this debt facility, primarily for use in supporting the advancement of its product development programs and proprietary technologies.
CORI: 7.00 (-0.05)
Corium International (CORI) Jumps: Stock Moves 14.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 8:25AM CST
Corium International (CORI) was a big mover last session, with shares rising over 14% on the day.
IPXL: 39.51 (+0.69), CORI: 7.00 (-0.05), AKRX: 47.28 (-0.25), MYL: 55.85 (+1.34)
Corium net loss improves in FY2014
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 6:26AM CST
CORI: 7.00 (-0.05)
Corium beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 3:15PM CST
CORI: 7.00 (-0.05)
Corium Reports Fiscal Year-End 2014 Financial Results and Recent Corporate Developments
GlobeNewswire - Mon Nov 17, 3:05PM CST
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the fiscal year ended September 30, 2014 and reported on recent corporate developments.
CORI: 7.00 (-0.05)
Corium to Report Fiscal Year-end 2014 Financial Results on Monday, November 17, 2014
GlobeNewswire - Tue Nov 11, 3:05PM CST
Corium International, Inc. (Nasdaq:CORI) today announced that it will report financial results for the fiscal year ended September 30, 2014 on Monday, November 17, 2014 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results.
CORI: 7.00 (-0.05)
Corium International (CORI) Jumps: Stock Adds 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 8:52AM CDT
Corium International (CORI) was a big mover last session, with shares rising nearly 9% on the day.
MNK: 115.01 (+2.51), LCI: 57.78 (-0.91), CORI: 7.00 (-0.05), CEMP: 27.68 (+1.25)
Leon Cooperman Picks Ocwen, Altisource Tumble
at The Street - Tue Oct 21, 2:30PM CDT
Corinthian Colleges Inc (NASDAQ:COCO), Gulf Coast Ultra Deep Royalty Trust – Royalty Trust Unit (NASDAQ:GULTU) and Corium International Inc (NASDAQ:CORI) are making notable climbs on the marke...
CORI: 7.00 (-0.05), ASPS: 22.32 (+0.09), OCN: 9.10 (+0.09), COCO: 0.02 (-0.01), GULTU: 0.99 (-0.01)
